Cardiology Today

Welcome to Cardiology Today – Recorded September 08, 2025. This episode summarizes 1 key cardiology studies on topics like Urgent Surgery and Fibrinolytic Therapy. Key takeaway: Urgent Surgery vs Thrombolysis for PVT?. Article Links: Article 1: Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/ Featured Articles Article 1: Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40574603 Summary: This randomized controlled trial compared urgent surgery with fibrinolytic therapy using low-dose, slow-infusion tissue plasminogen activator for symptomatic left-sided prosthetic valve thrombosis. The primary outcome was complete clinical response defined as resolution of symptoms and significant improvement in valve function, which was likely to be impacted by the occurrence of major adverse cardiovascular events and mortality. This study provides insights into the optimal treatment strategy for this serious complication, especially in settings where resources are limited. Transcript Today’s date is September 08, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Urgent surgery versus fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial. This randomized controlled trial compared urgent surgery with fibrinolytic therapy using low-dose, slow-infusion tissue plasminogen activator for symptomatic left-sided prosthetic valve thrombosis. The primary outcome was complete clinical response defined as resolution of symptoms and significant improvement in valve function, which was likely to be impacted by the occurrence of major adverse cardiovascular events and mortality. This study provides insights into the optimal treatment strategy for this serious complication, especially in settings where resources are limited. Thank you for listening. Don’t forget to subscribe. Keywords Urgent Surgery, Fibrinolytic Therapy, Prosthetic Valve Thrombosis. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Urgent Surgery vs Thrombolysis for PVT? 09/08/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 06, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and percutaneous coronary intervention. Key takeaway: Oxygen Uptake Recovery Predicts HCM Treatment Response. Article Links: Article 1: Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial. (Circulation) Article 2: Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. (Circulation) Article 3: Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA. (Circulation) Article 4: The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/ Featured Articles Article 1: Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40910189 Summary: This study from the United Kingdom Mini Mitral trial used wearable accelerometers to compare physical activity recovery after mitral valve surgery via sternotomy versus minimally invasive thoracoscopically guided right minithoracotomy. Results indicated no significant difference in physical activity levels between the two surgical approaches post-surgery. Accelerometer data provides an objective measure of recovery, suggesting both techniques lead to similar functional outcomes. Article 2: Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40910168 Summary: This substudy of the SEQUOIA-Hypertrophic Cardiomyopathy trial evaluated post-exercise oxygen uptake recovery as a measure of cardiac performance in patients with obstructive hypertrophic cardiomyopathy and dyspnea on exertion. The study identified easily derived oxygen uptake recovery measures correlated with cardiac function and response to disease-specific treatment. These novel oxygen uptake recovery patterns offer a cardiospecific and potentially prognostic tool for assessing treatment efficacy in hypertrophic cardiomyopathy. Article 3: Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40910165 Summary: The International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial investigated health status outcomes in patients with chronic coronary disease undergoing percutaneous coronary intervention versus coronary artery bypass grafting. The study found that an invasive strategy, percutaneous coronary intervention or coronary artery bypass grafting, resulted in better health status outcomes compared to a conservative medical strategy for patients with chronic coronary disease. Further research is needed to determine if the benefits of invasive management were driven more by percutaneous coronary intervention or coronary artery bypass grafting. Article 4: The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40911366 Summary: This review article discusses current and emerging targets for lipid-lowering therapies beyond low density lipoprotein cholesterol. It highlights the importance of triglycerides, apolipoprotein B, and lipoprotein(a) as contributors to residual cardiovascular risk despite statin therapy. The review explores molecular mechanisms and translational implications of therapies targeting these alternative lipid pathways, emphasizing the need for a multifaceted approach to manage dyslipidemia. Transcript Today’s date is September 06, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial. This study from the United Kingdom Mini Mitral trial used wearable accelerometers to compare physical activity recovery after mitral valve surgery via sternotomy versus minimally invasive thoracoscopically guided right minithoracotomy. Results indicated no significant difference in physical activity levels between the two surgical approaches post-surgery. Accelerometer data provides an objective measure of recovery, suggesting both techniques lead to similar functional outcomes. Article number two. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Subs

Welcome to Cardiology Today – Recorded September 05, 2025. This episode summarizes 2 key cardiology studies on topics like Clinical Trials and Protein Phosphatase 5. Key takeaway: Arachidonic Acid Drives Post-Infarct Inflammation. Article Links: Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. (European heart journal) Article 2: Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/ Featured Articles Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40905492 Summary: This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction. Article 2: Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40905476 Summary: This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies. Transcript Today’s date is September 05, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction. Article number two. Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies. Thank you for listening. Don’t forget to subscribe. Keywords Clinical Trials, Protein Phosphatase 5, Arachidonic Acid, Heart Failure, Macrophages, Myocardial Infarction, Cardiorenal Metabolic Syndrome, Inflammation, Chronic Kidney Disease, Glomerular Filtration Rate. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Arachidonic Acid Drives Post-Infarct Inflammation 09/05/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 04, 2025. This episode summarizes 5 key cardiology studies on topics like gestational hypertension and Mendelian randomization. Key takeaway: Clonal Hematopoiesis Links to CAD Mortality. Article Links: Article 1: Clinical care of family members of patients with dilated cardiomyopathy. (European heart journal) Article 2: Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study. (European heart journal) Article 3: Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. (European heart journal) Article 4: Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. (European heart journal) Article 5: Sexual minority populations and disparities in cardiovascular healthcare. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/ Featured Articles Article 1: Clinical care of family members of patients with dilated cardiomyopathy. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40902100 Summary: This consensus statement emphasizes tailoring cardiac screening regimens for family members of individuals with dilated cardiomyopathy based on both genetic and clinical information. It highlights the importance of genetic family screening after identifying a pathogenic variant in a proband, and recommends cardiac screening for all first-degree relatives. The approach advocates for individualized risk assessment at both individual and familial levels to optimize screening strategies. Article 2: Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900121 Summary: This genetic epidemiology study used Mendelian randomization to investigate the causal relationship between hypertensive disorders of pregnancy and later cardiovascular disease risk. Analyzing data from FinnGen and other consortia, the study aimed to determine if the observed associations between preeclampsia, gestational hypertension and cardiovascular outcomes reflect true causal pathways. These results could inform targeted prevention strategies for women with a history of hypertensive pregnancies. Article 3: Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900118 Summary: This analysis of the DEDICATE-DZHK6 trial examines sex-specific outcomes in patients with aortic stenosis undergoing transcatheter aortic valve implantation or surgical aortic valve replacement. While the main trial demonstrated non-inferiority of transcatheter aortic valve implantation compared to surgery, this pre-defined descriptive analysis focuses on differences in outcomes between men and women. Understanding these sex-specific nuances can help refine treatment strategies for aortic stenosis. Article 4: Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900105 Summary: This study investigated the link between clonal haematopoiesis of indeterminate potential and all-cause mortality in patients with angiographically confirmed coronary artery disease. Through deep sequencing of genes associated with clonal haematopoiesis of indeterminate potential in over 8,600 patients, the research identifies the prognostic relevance and explores the mechanisms by which clonal haematopoiesis of indeterminate potential, particularly TET2 mutations, impacts mortality in coronary artery disease. The findings may refine risk stratification and treatment strategies in patients with coronary artery disease. Article 5: Sexual minority populations and disparities in cardiovascular healthcare. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900101 Summary: This review highlights the increased risk of cardiovascular disease among sexual minority populations compared to heterosexual individuals, emphasizing the influence of minority stressors on cardiovascular health. It discusses the minority stress model, which posits that stressors across multiple levels contribute to cardiovascular disease risk in lesbian, gay, bisexual, queer, and other non-heterosexual people. Addressing these disparities requires understanding and mitigating minority stressors within the healthcare system. Transcript Today’s date is September 04, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Clinical care of family members of patients with dilated cardiomyopathy. This consensus statement emphasizes tailoring cardiac screening regimens for family members of individuals with di

Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 1 key cardiology studies on topics like adipose tissue and obesity. Key takeaway: Obesity’s Unclear Role in Heart Failure with Reduced Ejection. Article Links: Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/ Featured Articles Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40891153 Summary: The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction. Transcript Today’s date is September 03, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? This article discusses the unclear role of obesity and visceral adiposity in the development of Heart Failure with Reduced Ejection Fraction, contrasting it with their established role in Heart Failure with Preserved Ejection Fraction. The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction. Thank you for listening. Don’t forget to subscribe. Keywords adipose tissue, obesity, Heart Failure with Reduced Ejection Fraction, visceral adiposity, Heart Failure with Preserved Ejection Fraction. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Obesity’s Unclear Role in Heart Failure with Reduced Ejection 09/03/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 5 key cardiology studies on topics like comorbidities and cardiomyocytes. Key takeaway: Lipoprotein(a) Predicts Vascular Disease Risk. Article Links: Article 1: Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses’ Health Study II. (Circulation) Article 2: Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. (Circulation) Article 3: PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations. (Circulation) Article 4: Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. (Circulation) Article 5: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/ Featured Articles Article 1: Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses’ Health Study II. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40785542 Summary: This prospective study within the Nurses’ Health Study II found that women who experienced stalking, particularly those who obtained restraining orders, had a significantly higher risk of developing cardiovascular events. The increased risk highlights the long-term cardiovascular consequences of interpersonal violence and the potential need for targeted screening and intervention in women with a history of stalking. These findings underscore the importance of addressing violence as a cardiovascular risk factor. Article 2: Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40718930 Summary: This study evaluated lipoprotein a as a marker for extracoronary atherosclerotic vascular disease progression. Results indicated that elevated lipoprotein a levels are associated with a higher risk of developing extracoronary atherosclerotic vascular disease and related complications, suggesting it may serve as a useful prognostic biomarker. These results reinforce the need for considering lipoprotein a levels in risk assessment for atherosclerotic vascular disease. Article 3: PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40665909 Summary: This research investigated the role of PIEZO1 in hereditary hemorrhagic telangiectasia arteriovenous malformations. The study found that PIEZO1 is overexpressed in arteriovenous malformations associated with hereditary hemorrhagic telangiectasia, particularly those caused by activin receptor-like kinase 1 mutations. This suggests a potential therapeutic target for managing arteriovenous malformations in hereditary hemorrhagic telangiectasia. Article 4: Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40631661 Summary: This study identified PHF7 as a potent epigenetic factor that enhances the direct reprogramming of fibroblasts into cardiomyocytes in vitro. In a model of myocardial infarction, PHF7-mediated reprogramming improved cardiac function. These findings suggest PHF7 could be a key factor in developing cell-based therapies for ischemic heart disease. Article 5: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892534 Summary: This review article discusses the mechanisms and treatment of left ventricular hypertrophy and myocardial fibrosis in Heart Failure with Preserved Ejection Fraction. It highlights the role of comorbidities like hypertension, obesity, and diabetes in promoting adverse cardiac remodeling and fibrosis. The review emphasizes the need for targeted therapies addressing these underlying comorbidities to improve outcomes in Heart Failure with Preserved Ejection Fraction. Transcript Today’s date is September 03, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses’ Health Study II. This prospective study within the Nurses’ Health Study II found that women who experienced stalking, particularly those who obtained restraining orders, had a significantly higher risk of developing cardiovascular even

Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like coronary flow capacity and cardiovascular events. Key takeaway: AI Spots Vulnerable Plaques, Predicts MI Risk. Article Links: Article 1: Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD. (Journal of the American College of Cardiology) Article 2: Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study. (European heart journal) Article 3: Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. (European heart journal) Article 4: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study. (European heart journal) Article 5: Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/ Featured Articles Article 1: Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40866049 Summary: This prospective study examined neurocognitive dysfunction in adults with moderate to severe complex congenital heart disease. The study found a significant prevalence of neurocognitive deficits in this population, and identified risk factors such as atrial fibrillation, heart failure and repeated cardiac interventions that contribute to cognitive impairment. These findings highlight the need for routine neurocognitive screening and targeted interventions to improve long-term outcomes in adults with congenital heart disease. Article 2: Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40569854 Summary: This large, nationwide study from Sweden evaluated the association between adverse pregnancy outcomes and long-term stroke risk. Results demonstrated that women with a history of preterm delivery or who were small for gestational age experienced a significantly elevated long-term risk of stroke. These findings underscore the importance of considering adverse pregnancy outcomes as a risk factor for later-life cardiovascular disease and stroke prevention strategies. Article 3: Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40439159 Summary: The CENTURY trial investigated whether an intensive medical management strategy guided by coronary flow capacity assessment via positron emission tomography (PET) could improve outcomes in patients with stable chronic coronary artery disease compared to standard care. The study demonstrated that this comprehensive approach, using revascularization only for those with severely reduced coronary flow capacity, led to improvements in risk factors. It also reduced the need for subsequent revascularization procedures. Article 4: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888677 Summary: The PECTUS-AI study evaluated the use of artificial intelligence to identify thin-cap fibroatheromas, a high-risk plaque feature, using optical coherence tomography images in patients after myocardial infarction. The study found that the artificial intelligence algorithm accurately identified thin-cap fibroatheromas and was predictive of future adverse cardiovascular events. This suggests that artificial intelligence can improve risk stratification and potentially guide targeted interventions in patients with coronary artery disease. Article 5: Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888584 Summary: The OPINION trial investigated the efficacy of surgical left atrial appendage occlusion in patients undergoing valvular surgery who did not have atrial fibrillation but had a CHA₂DS₂-VASc score of 2 or greater. The study did not demonstrate a significant reduction in postoperative thromboembolic events with surgical left atrial appendage occlusion compared to no occlusion. Therefore, prophylactic surgical left atrial appendage occlusion cannot be recommended for stroke prevention in this patient population. Transcript Today’s date is September 02, 2025. Welcome to Cardiology Today. Her

Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and older adults. Key takeaway: Aficamten Superior to Metoprolol in HCM?. Article Links: Article 1: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. (The New England journal of medicine) Article 2: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. (The New England journal of medicine) Article 3: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine) Article 4: RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. (The New England journal of medicine) Article 5: High-Dose Influenza Vaccine to Reduce Hospitalizations. (The New England journal of medicine) Full episode page: https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/ Featured Articles Article 1: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888716 Summary: This open-label randomized trial in Denmark and Norway found no significant difference in the composite outcome of death from any cause, new myocardial infarction, or hospitalization for heart failure between patients with a left ventricular ejection fraction of 40 percent or greater who received long-term beta-blocker therapy and those who did not after myocardial infarction. Specifically, the study challenges the routine use of beta-blockers in this patient population in the era of modern reperfusion and secondary prevention. The findings suggest a need to re-evaluate guidelines regarding long-term beta-blocker use post myocardial infarction in patients without heart failure or reduced ejection fraction. Article 2: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888702 Summary: This open-label randomized trial in Spain and Italy evaluated beta-blocker therapy versus no beta-blocker therapy in acute myocardial infarction patients with or without ST-segment elevation, but without reduced ejection fraction. The study found no significant difference in the primary composite outcome of all-cause death, myocardial infarction, hospitalization for heart failure, stroke, or major bleeding at a median of 3.5 years, suggesting that routine beta-blocker use in this contemporary setting may not provide additional benefit. This calls into question current guideline recommendations that are based on older trials before routine reperfusion and complete revascularization strategies. Article 3: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888697 Summary: This international, double-blind, randomized trial compared aficamten monotherapy to metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. The study concluded that aficamten led to a statistically significantly greater reduction from baseline in the Valsalva left ventricular outflow tract gradient at week 12 compared to metoprolol; aficamten also resulted in a greater proportion of patients achieving an improvement of at least one New York Heart Association functional class. These findings suggest aficamten may be a more effective monotherapy option than metoprolol for managing symptomatic obstructive hypertrophic cardiomyopathy. Article 4: RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888695 Summary: This pragmatic, open-label trial evaluated the Respiratory Syncytial Virus prefusion F protein-based vaccine in adults 60 years or older. The study found that the vaccine did not significantly reduce the risk of hospitalization for Respiratory Syncytial Virus-related lower respiratory tract disease, though there was a trend towards lower hospitalization rates. The researchers suggest further research is warranted to assess the vaccine’s effectiveness in preventing more severe Respiratory Syncytial Virus outcomes in this population. Article 5: High-Dose Influenza Vaccine to Reduce Hospitalizations. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888694 Summary: This registry-based, open-label trial evaluated the effectiveness of high-dose inactivated influenza vaccine versus standard-dose vaccine in adults 65 years or older. Results showed no significant reduction in hospitalizations for influenza or pneumonia with the high-dose vaccine compared to the standard-dose vaccine. This suggests that, despite prior evidence of superior protection against laboratory-confirmed influenza, the hig

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Olezarsen and influenza vaccine. Key takeaway: Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results. Article Links: Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. (The New England journal of medicine) Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. (The New England journal of medicine) Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. (The New England journal of medicine) Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. (The New England journal of medicine) Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine) Full episode page: https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/ Featured Articles Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888739 Summary: This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk. Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888734 Summary: This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population. Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888730 Summary: This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation. Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888720 Summary: This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly. Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888717 Summary: This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capacity and patient-reported health status compared to placebo in this patient group. This suggests mavacamten could be a beneficial treatment option for symptomatic nonobstructive Hypertrophic Cardiomyopathy, expanding its therapeutic applications. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk. Article number two. Apixaban for Extended Treatment of Provoked Venous Thromboembolism.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like stent implantation and community health workers. Key takeaway: Aspirin: Is It Safe to Stop It Early?. Article Links: Article 1: Home-Based Care for Hypertension in Rural South Africa. (The New England journal of medicine) Article 2: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. (The New England journal of medicine) Article 3: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. (The New England journal of medicine) Article 4: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. (The New England journal of medicine) Article 5: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. (The New England journal of medicine) Full episode page: https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/ Featured Articles Article 1: Home-Based Care for Hypertension in Rural South Africa. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888742 Summary: This open-label trial in South Africa investigated a home-based hypertension care model involving patient blood pressure monitoring, community health worker home visits for data collection and medication delivery, and remote nurse-led decision making. The intervention significantly improved blood pressure control compared to usual care, demonstrating the effectiveness of community-based strategies in managing hypertension in resource-limited settings. This approach holds promise for expanding access to and improving hypertension management in similar populations. Article 2: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888737 Summary: This registry-based clinical trial assessed whether adding ticagrelor to aspirin, compared with aspirin alone, reduces cardiovascular events after coronary-artery bypass grafting for acute coronary syndrome. The study found no significant difference in the composite outcome of all-cause mortality, myocardial infarction, stroke, or repeat revascularization between the ticagrelor-aspirin and aspirin-only groups at one year. Therefore, aspirin monotherapy appears sufficient for most patients following coronary artery bypass grafting post acute coronary syndrome. Article 3: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888726 Summary: This multicenter trial examined early aspirin discontinuation after percutaneous coronary intervention in acute myocardial infarction patients deemed low-risk. Patients who discontinued aspirin after one week and continued P2Y12 inhibitor monotherapy had similar rates of major adverse cardiovascular events compared to those receiving twelve months of dual antiplatelet therapy. This suggests that early aspirin withdrawal may be a safe strategy in select low-risk acute myocardial infarction patients undergoing percutaneous coronary intervention. Article 4: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888725 Summary: This randomized, placebo-controlled trial evaluated the role of aspirin in chronic coronary syndrome patients on long-term oral anticoagulation after previous stent implantation. The addition of aspirin to oral anticoagulation did not significantly reduce the risk of thrombotic events but did significantly increase the risk of major bleeding. These findings support the strategy of avoiding aspirin in chronic coronary syndrome patients already receiving oral anticoagulants. Article 5: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888723 Summary: This study investigated whether P2Y12 inhibitor monotherapy without aspirin, initiated shortly after successful percutaneous coronary intervention, is effective and safe for patients with acute coronary syndromes. Early aspirin withdrawal and P2Y12 inhibitor monotherapy, compared to standard dual antiplatelet therapy, resulted in similar rates of the primary composite outcome of death, myocardial infarction, stroke, or major bleeding. Thus, early aspirin cessation with P2Y12 inhibitor monotherapy appears non-inferior to dual antiplatelet therapy in acute coronary syndrome patients post percutaneous coronary intervention. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Home-Based Care for Hypertension in Rural South Africa. This open-label trial in South Africa inve

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like hypokalemia and cardiac wasting. Key takeaway: Low Potassium Linked to Atrial Fibrillation Risk. Article Links: Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. (European heart journal) Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. (European heart journal) Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders. (European heart journal) Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. (European heart journal) Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884219 Summary: This study demonstrated that KCNH2-specific suppression-and-replacement gene therapy, delivered via adeno-associated virus serotype 9, effectively corrected the short QT phenotype in a transgenic rabbit model of type 1 Short QT Syndrome. Specifically, the gene therapy normalized cardiac repolarization and QT intervals, addressing the underlying genetic cause of the arrhythmia. These results suggest a potential therapeutic strategy for Short QT Syndrome using targeted gene therapy to prevent ventricular arrhythmias and sudden cardiac death. Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884211 Summary: Analysis of the REBOOT trial data showed that in post-myocardial infarction patients with left ventricular ejection fraction greater than 40 percent, beta-blocker therapy did not significantly reduce the risk of death or new myocardial infarction in either men or women. Furthermore, women experienced a nominally significant increase in the composite outcome of all-cause death or new myocardial infarction with beta-blocker use, although this was not statistically significant after adjustment. These findings suggest a need for re-evaluation of routine beta-blocker use after myocardial infarction in patients with preserved ejection fraction, with consideration for potential sex-specific effects. Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884202 Summary: This post hoc analysis of the LOOP study, utilizing data from patients with stroke risk factors and implanted loop recorders, revealed a significant association between low plasma potassium levels and the occurrence of atrial fibrillation. Specifically, each 0.1 millimole per liter decrease in plasma potassium was associated with a 7 percent increased risk of atrial fibrillation detection. These findings highlight the importance of maintaining adequate potassium levels in individuals at risk for atrial fibrillation and suggest that potassium monitoring and management could be a potential strategy for atrial fibrillation prevention. Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884168 Summary: This study found that elevated circulating levels of imidazole propionate, a metabolite produced by gut microbiota, are associated with increased cardiometabolic risk in patients with coronary artery disease. High imidazole propionate levels were predictive of major adverse cardiovascular events in independent cohorts of patients with acute coronary syndrome. These findings suggest that imidazole propionate may serve as a biomarker for identifying high-risk patients with coronary artery disease and highlight the potential role of gut microbiota modulation in cardiovascular disease prevention and management. Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884070 Summary: The EMPATICC trial, studying patients with advanced cancer receiving palliative care, is an ongoing trial designed to evaluate the safety and efficacy of heart failure therapies in this unique patient population. The trial

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and aspirin resistance. Key takeaway: Aspirin Dose Upregulation Fails After Acute Coronary Syndrome. Article Links: Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. (European heart journal) Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. (European heart journal) Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. (European heart journal) Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. (European heart journal) Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884758 Summary: This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population. Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884757 Summary: The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events. Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884558 Summary: The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population. Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884439 Summary: This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine’s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on cardiovascular events, suggesting targeted respiratory protection. Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884413 Summary: standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. The DANFLU-2 trial compared high-dose versus standard-dose inactivated influenza vaccine in adults with and without atherosclerotic cardiovascular disease. The study showed no significant difference in cardiovascular or respiratory outcomes between the two vaccine doses. This indicates that high-dose influenza vaccination does not provide superior cardiovascular protection compared to standard-dose in this population. Transcript Today’s date is September 01, 2025

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and thrombosis. Key takeaway: Lipoprotein(a) Elevates Family Cardiac Risk. Article Links: Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. (European heart journal) Article 2: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. (European heart journal) Article 3: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. (European heart journal) Article 4: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. (European heart journal) Article 5: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886161 Summary: This analysis of the GALACTIC-HF trial found that lower serum magnesium concentrations were associated with a higher risk of the primary composite outcome in patients with Heart Failure with Reduced Ejection Fraction. Specifically, each 0.1 milligram per deciliter decrease in magnesium was linked to a statistically significant increase in the risk of heart failure hospitalization or cardiovascular death. This suggests that serum magnesium levels may serve as a prognostic marker in Heart Failure with Reduced Ejection Fraction. Article 2: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132 Summary: This registry-based study revealed that first-degree relatives of individuals with elevated Lipoprotein(a) levels had a significantly increased risk of major adverse cardiovascular events, including myocardial infarction and ischemic stroke, compared to those without elevated Lipoprotein(a). This elevated risk highlights the familial clustering of cardiovascular disease related to Lipoprotein(a) and underscores the importance of screening family members of individuals with high Lipoprotein(a). The study reinforces Lipoprotein(a) as a causal factor in atherosclerotic cardiovascular disease. Article 3: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886063 Summary: This study characterized reticulated platelets in patients with coronary artery disease, demonstrating their hyperreactive and prothrombotic nature through enhanced signaling pathways and increased interaction with leukocytes. The research identified specific molecular targets within these platelets that could be exploited for novel antiplatelet therapies, potentially improving outcomes in coronary artery disease patients who exhibit suboptimal responses to current treatments. These findings implicate reticulated platelets as key contributors to thrombotic risk in coronary artery disease. Article 4: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886061 Summary: The SEMA-VR CardioLink-15 trial demonstrated that semaglutide treatment in high-risk patients favorably modulates bone marrow-derived progenitor cells, shifting them toward an anti-inflammatory and pro-regenerative profile. Specifically, semaglutide increased the levels of circulating vascular regenerative cells, suggesting a potential mechanism by which glucagon-like peptide-1 receptor agonists reduce major atherosclerotic cardiovascular events. These findings suggest that semaglutide may promote vascular repair and reduce atherothrombotic risk through modulation of vascular progenitor cells. Article 5: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886060 Summary: This study demonstrated that CRISPR activation effectively upregulated the expression of the Filamin C gene in mice carrying a

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like PRADA II trial and breast cancer. Key takeaway: TAVR: Minimalist Approach Proven Safe and Effective. Article Links: Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation) Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulation) Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. (Circulation) Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. (Circulation) Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884047 Summary: This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments. Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879562 Summary: This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy. Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878766 Summary: The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation. Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878676 Summary: This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potential targets for developing new treatments for patients with antiphospholipid syndrome vasculopathy. Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179 Summary: The TAILORED-CHIP trial investigated tailored antiplatelet strategies involving temporal modulation of platelet inhibition intensity in high-risk patients undergoing complex percutaneous coronary intervention. The trial found that the tailored antiplatelet strategy did not reduce major adverse cardiovascular events compared to standard dual antiplatelet therapy. The study suggests that a tailored approach based on platelet function testing may not provide superior outcomes in this patient population. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Arti

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like biomarker and mitral regurgitation. Key takeaway: Cerebral Protection Mitigates TAVI Cognitive Decline. Article Links: Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. (Circulation) Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. (Circulation) Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. (Circulation) Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation) Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. (Circulation) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886109 Summary: The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes. Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884786 Summary: This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure. Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884774 Summary: This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions. Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884771 Summary: This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. The results will show whether ivabradine is a safe and effective alternative to beta-blockers for heart rate control in this setting. Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884768 Summary: This three-year follow-up of the NOTION-2 trial compared transcatheter aortic valve replacement to surgical aortic valve replacement in younger, low-risk patients with severe tricuspid or bicuspid aortic stenosis. The study evaluated mid-term outcomes in patients aged 60 to 75 years undergoing either transcatheter aortic valve replacement or surgery. The trial will help inform treatment decisions for younger patients with aortic stenosis. <h3> Transcript</h3> <div style=”background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;”> <p><em>Today’s date is Septem

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Cardiac Glycoside and Artificial Intelligence. Key takeaway: Rehab Improves Outcomes Post-Myocardial Infarction. Article Links: Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. (The New England journal of medicine) Article 2: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine) Article 3: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine) Article 4: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine) Article 5: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434 Summary: This international, double-blind, placebo-controlled trial evaluated digitoxin in patients with chronic heart failure who had a left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV or a left ventricular ejection fraction of 30 percent or less and a New York Heart Association functional class of II. The study found no significant difference between digitoxin and placebo in the composite outcome of death from cardiovascular causes or hospitalization for worsening heart failure. These findings do not support the use of digitoxin in patients with heart failure and reduced ejection fraction. Article 2: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431 Summary: This multicenter, randomized trial assessed the benefit of multidomain rehabilitation interventions in older patients, specifically those 65 years of age or older with myocardial infarction and impaired physical performance. Patients receiving comprehensive rehabilitation, including cardiovascular risk factor control, dietary counseling, and exercise training, experienced significant improvements in physical performance compared to those receiving usual care. This trial supports the use of multidomain rehabilitation to improve outcomes in older adults following myocardial infarction. Article 3: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429 Summary: This multicenter, open-label, event-driven, randomized superiority trial investigated whether increasing plasma potassium levels reduces the risk of ventricular arrhythmias in high-risk patients. Participants with an implantable cardioverter-defibrillator were enrolled, and the study found that actively increasing plasma potassium levels to the high-normal range did not reduce the risk of ventricular arrhythmias or all-cause mortality. Therefore, actively increasing potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias is not supported. Article 4: Reduction of Antihypertensive Treatment in Nursing Home Residents. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421 Summary: This multicenter, randomized, controlled trial evaluated the effects of reducing antihypertensive treatment in frail, older nursing home residents. The study found that a protocol-driven strategy of progressive reduction of antihypertensive treatment did not significantly reduce the risk of death or cardiovascular events compared to usual care. These results suggest that carefully monitored reduction of antihypertensive medications may be a safe strategy in this population. Article 5: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124 Summary: This study assessed the condition-specific performance of artificial intelligence enhanced electrocardiogram models, to detect specific anatomical and functional cardiac abnormalities using data from electronic health records and prospective cohorts. The study demonstrated that artificial intelligence electrocardiogram models can identify distinct cardiovascular phenotypes, but also capture broader cardiovascular risk associations. This suggests artificial intelligen

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like bleeding and NOTION-2 trial. Key takeaway: Ivabradine for MINS: A Beta-Blocker Alternative?. Article Links: Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. (Circulation) Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation) Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. (Circulation) Article 4: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation) Article 5: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulation) <p>Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/</p> <h3> Full Episode Summary</h3> <p>This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details.</p> <h3> Featured Articles</h3> <h4>Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884774″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884774</a></p> <p><strong>Summary:</strong> This multicenter randomized controlled trial evaluated whether using biomarker-based Atrial Fibrillation Better Care risk scores to guide treatment decisions improves outcomes in patients with atrial fibrillation. The study informed investigators of each patient’s ABC-AF-stroke, bleeding, and heart failure risk scores to guide multidimensional treatments; however, the full results and clinical implications will be crucial to understanding its impact.</p> <h4>Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884771″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884771</a></p> <p><strong>Summary:</strong> This randomized controlled trial investigated ivabradine, a selective heart rate-lowering agent, to prevent myocardial injury after noncardiac surgery. The study compared ivabradine to placebo in patients at risk for atherosclerotic disease undergoing noncardiac surgery, aiming to reduce perioperative myocardial infarction without the hemodynamic instability associated with beta-blockers.</p> <h4>Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884768″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884768</a></p> <p><strong>Summary:</strong> The NOTION-2 trial’s three-year follow-up compared tran… (Full details on website)The post Ivabradine for MINS: A Beta-Blocker Alternative? 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like mitral valve surgery and frailty. Key takeaway: De-escalating Hypertension in Frail Elderly is Safe. Article Links: Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine) | Article 2: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine) | Article 3: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation) | Article 4: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. (Circulation) | Article 5: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. (Circulation) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429 Summary: This Danish, multi-center, open-label, randomized trial investigated actively increasing plasma potassium levels in patients at high risk for ventricular arrhythmias who had an implantable cardioverter-defibrillator. The study was stopped early due to slow enrollment and a low number of events, concluding that an active strategy of increasing plasma potassium was not associated with a lower risk of ventricular arrhythmias or death, but did show a potential association with an increased risk of hyperkalemia. This suggests further research is necessary to determine optimal potassium management in this high-risk population. Article 2: Reduction of Antihypertensive Treatment in Nursing Home Residents. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421 Summary: This French, multi-center, randomized, controlled trial examined the effects of reducing antihypertensive medications in nursing home residents aged 80 or older with systolic blood pressure below 130 millimeters of mercury. Results showed that a protocol-driven strategy of progressive antihypertensive treatment reduction did not significantly increase the risk of death or serious adverse events compared to usual care. The study suggests that de-escalation of antihypertensive therapy may be safe in frail, older adults in nursing homes. Article 3: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124 Summary: This study investigated the performance of artificial intelligence-enhanced electrocardiogram models to detect specific cardiac conditions versus broad cardio… (Full details on website)The post De-escalating Hypertension in Frail Elderly is Safe 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Risk Factors and Exercise Training. Key takeaway: Rehab After MI: Impact on Older Patients. Article Links: Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431 Summary: This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiovascular Risk Factors, Exercise Training, Myocardial Infarction, Cardiac Rehabilitation, Geriatric Cardiology. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Rehab After MI: Impact on Older Patients 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Mortality and Hospitalization.. Key takeaway: Biomarker-guided treatments show no outcome benefits. Article Links: Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. (The New England journal of medicine) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434 Summary: This double-blind, placebo-controlled trial investigated digitoxin’s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double-blind, placebo-controlled trial investigated digitoxin’s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiovascular Mortality, Hospitalization., Heart Failure with Reduced Ejection Fraction, Digitoxin, Cardiac Glycosides. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Digitoxin Fails in Heart Failure Trial 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits. Article Links: Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132 Summary: This Swedish registry study investigated major cardiovascular event risk in first-degree relatives of individuals with elevated Lipoprotein(a). The study found that relatives of probands with high Lipoprotein(a) had an increased risk of myocardial infarction, ischemic stroke, and death, particularly when the proband experienced premature cardiovascular disease, highlighting the need for familial screening and risk stratification. These findings suggest monitoring family members of patients with high Lipoprotein(a) could lead to earlier interventions and improve cardiovascular outcomes. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This Swedish registry study investigated major cardiovascular event risk in first-degree relatives of individuals with elevated Lipoprotein(a). The study found that relatives of probands with high Lipoprotein(a) had an increased risk of myocardial infarction, ischemic stroke, and death, particularly when the proband experienced premature cardiovascular disease, highlighting the need for familial screening and risk stratification. These findings suggest monitoring family members of patients with high Lipoprotein(a) could lead to earlier interventions and improve cardiovascular outcomes. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiology, Heart Disease, Clinical Research, NEJM, JACC. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Lipoprotein(a) Elevates Family Cardiac Risk 09/01/25 first appeared on Cardiology Today.

<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like serum magnesium and GALACTIC-HF trial. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p><p>Article Links: Article 1: <a href=’https://pubmed.ncbi.nlm.nih.gov/40886161′>Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</a> (European heart journal)</p><p>Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/</p> <h3> Full Episode Summary</h3> <p>This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details.</p> <h3> Featured Articles</h3> <h4>Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</h4> <p><strong>Journal:</strong> European heart journal</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40886161″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40886161</a></p> <p><strong>Summary:</strong> In patients with Heart Failure with Reduced Ejection Fraction enrolled in the GALACTIC-Heart Failure trial, researchers evaluated the association between serum magnesium levels and clinical outcomes. The study found that both low and high magnesium concentrations were independently associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. This suggests that maintaining optimal serum magnesium levels may be important in managing patients with Heart Failure with Reduced Ejection Fraction.</p> <h3> Transcript</h3> <div style=”background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;”> <p><em>Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p> Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. In patients with Heart Failure with Reduced Ejection Fraction enrolled in the GALACTIC-Heart Failure trial, researchers evaluated the association between serum magnesium levels and clinical outcomes. The study found that both low and high magnesium concentrations were independently associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. This suggests that maintaining optimal serum magnesium levels may be important in managing patients with Heart Failure with Reduced Ejection Fraction. <p><em>Thank you for listening. Tap ‘more’ for full notes and links.</em></p> </div> <h3> Keywords</h3> <p>serum magnesium, GALACTIC-HF trial, heart failure events, cardiovascular death, Heart Failure with Reduced Ejection Fraction.</p> <h3> About</h3> <p>Concise summaries of cardiovascular research for professionals.</p> <p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p>The post Magnesium Levels Impact HFrEF Outcomes 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits. Article Links: Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179 Summary: This trial evaluated a tailored antiplatelet strategy, modulating platelet inhibition intensity, in high-risk patients undergoing complex PCI. The study’s findings will likely influence future antiplatelet guidelines for this specific patient population. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. This trial evaluated a tailored antiplatelet strategy, modulating platelet inhibition intensity, in high-risk patients undergoing complex PCI. The study’s findings will likely influence future antiplatelet guidelines for this specific patient population. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiology, Heart Disease, Clinical Research, NEJM, JACC. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Tailored Antiplatelet Rx in Complex PCI: TAILORED-CHIP 09/01/25 first appeared on Cardiology Today.

<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t <h3> Full Episode Summary</h3> <p>This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details.</p> <h3> Featured Articles</h3> <h4>Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884771″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884771</a></p> <p><strong>Summary:</strong> This study investigated ivabradine to prevent myocardial injury after noncardiac surgery. The trial found no significant reduction in MINS with ivabradine compared to placebo, suggesting ivabradine is not effective for this purpose.</p> <h3> Transcript</h3> <div style=”background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;”> <p><em>Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p> Article number one. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This study investigated ivabradine to prevent myocardial injury after noncardiac surgery. The trial found no significant reduction in MINS with ivabradine compared to placebo, suggesting ivabradine is not effective for this purpose. <p><em>Thank you for listening. Tap ‘more’ for full notes and links.</em></p> </div> <h3> Keywords</h3> <p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p> <h3> About</h3> <p>Concise summaries of cardiovascular research for professionals.</p> <p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p>The post Ivabradine Fails to Prevent MINS After Surgery 09/01/25 first appeared on Cardiology Today.

<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t <h3> Full Episode Summary</h3> <p>This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details.</p> <h3> Featured Articles</h3> <h4>Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40886109″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40886109</a></p> <p><strong>Summary:</strong> This international registry study evaluated outcomes of mitral valve surgery for mitral regurgitation in a real-world setting. The study found significant variations in surgical approaches and patient selection, with in-hospital mortality rates influenced by preoperative risk factors and the type of surgery performed. These findings highlight the need for standardized guidelines and improved risk stratification to optimize outcomes in patients undergoing mitral valve surgery.</p> <h3> Transcript</h3> <div style=”background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;”> <p><em>Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p> Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. This international registry study evaluated outcomes of mitral valve surgery for mitral regurgitation in a real-world setting. The study found significant variations in surgical approaches and patient selection, with in-hospital mortality rates influenced by preoperative risk factors and the type of surgery performed. These findings highlight the need for standardized guidelines and improved risk stratification to optimize outcomes in patients undergoing mitral valve surgery. <p><em>Thank you for listening. Tap ‘more’ for full notes and links.</em></p> </div> <h3> Keywords</h3> <p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC</p> <h3> About</h3> <p>Concise summaries of cardiovascular research for professionals.</p> <p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p>The post Mitral Regurgitation Surgery: Optimizing Outcomes 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits. Article Links: Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124 Summary: This study found that AI-ECG models, while designed for specific cardiac abnormalities, often function as broader cardiovascular risk markers rather than condition-specific classifiers. This finding suggests caution is needed when interpreting AI-ECG results, as a positive result may indicate general cardiovascular risk rather than a specific condition. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study found that AI-ECG models, while designed for specific cardiac abnormalities, often function as broader cardiovascular risk markers rather than condition-specific classifiers. This finding suggests caution is needed when interpreting AI-ECG results, as a positive result may indicate general cardiovascular risk rather than a specific condition. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiology, Heart Disease, Clinical Research, NEJM, JACC. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post AI-ECG: Broad CVD Risk Marker, Not Specific Classifier 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits. Article Links: Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421 Summary: This study found that in frail, elderly nursing home residents taking multiple antihypertensives with systolic blood pressure below 130, a protocol driven reduction in medication did not significantly increase the risk of falls, serious adverse events, or mortality compared to usual care. These findings suggest that de-escalation of antihypertensive therapy may be safe in this vulnerable population, potentially reducing polypharmacy and improving quality of life. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Reduction of Antihypertensive Treatment in Nursing Home Residents. This study found that in frail, elderly nursing home residents taking multiple antihypertensives with systolic blood pressure below 130, a protocol driven reduction in medication did not significantly increase the risk of falls, serious adverse events, or mortality compared to usual care. These findings suggest that de-escalation of antihypertensive therapy may be safe in this vulnerable population, potentially reducing polypharmacy and improving quality of life. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiology, Heart Disease, Clinical Research, NEJM, JACC. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post De-escalate BP Meds in Frail Elderly? NEJM Trial 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits. Article Links: Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429 Summary: This study investigates actively increasing plasma potassium levels to the high-normal range in high-risk ICD patients to reduce ventricular arrhythmias. The multicenter trial in Denmark aims to determine if maintaining high-normal potassium levels reduces arrhythmia risk in this vulnerable population. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This study investigates actively increasing plasma potassium levels to the high-normal range in high-risk ICD patients to reduce ventricular arrhythmias. The multicenter trial in Denmark aims to determine if maintaining high-normal potassium levels reduces arrhythmia risk in this vulnerable population. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiology, Heart Disease, Clinical Research, NEJM, JACC. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post High Potassium Reduces ICD Shocks in Arrhythmia 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits. Article Links: Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431 Summary: This randomized trial found that a multidomain rehabilitation program including cardiovascular risk factor control, dietary counseling, and exercise training significantly improved physical performance and reduced major adverse cardiovascular events in older patients with impaired physical performance one month post myocardial infarction. The findings suggest that comprehensive rehabilitation should be considered for older myocardial infarction patients to improve outcomes. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This randomized trial found that a multidomain rehabilitation program including cardiovascular risk factor control, dietary counseling, and exercise training significantly improved physical performance and reduced major adverse cardiovascular events in older patients with impaired physical performance one month post myocardial infarction. The findings suggest that comprehensive rehabilitation should be considered for older myocardial infarction patients to improve outcomes. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiology, Heart Disease, Clinical Research, NEJM, JACC. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Rehab Boosts Outcomes Post-MI in Elderly Patients 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132 Summary: This study found that first-degree relatives of individuals with elevated lipoprotein(a) levels had a modestly increased risk of major adverse cardiovascular events compared to the general population, even without directly measured lipoprotein(a) levels. This suggests a potential familial risk associated with elevated lipoprotein(a) requiring further investigation and possibly screening strategies. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This study found that first-degree relatives of individuals with elevated lipoprotein(a) levels had a modestly increased risk of major adverse cardiovascular events compared to the general population, even without directly measured lipoprotein(a) levels. This suggests a potential familial risk associated with elevated lipoprotein(a) requiring further investigation and possibly screening strategies. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Familial Lp(a) Raises Cardiac Event Risk 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886161 Summary: The GALACTIC-Heart Failure trial, a randomized controlled trial investigating omecamtiv mecarbil versus placebo in heart failure patients with left ventricular ejection fraction of thirty-five percent or less, was used to assess the prognostic significance of serum magnesium concentrations. The study found that both low and high magnesium levels were associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. These findings suggest that maintaining optimal serum magnesium concentrations may be important for improving outcomes in patients with heart failure with reduced ejection fraction. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. The GALACTIC-Heart Failure trial, a randomized controlled trial investigating omecamtiv mecarbil versus placebo in heart failure patients with left ventricular ejection fraction of thirty-five percent or less, was used to assess the prognostic significance of serum magnesium concentrations. The study found that both low and high magnesium levels were associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. These findings suggest that maintaining optimal serum magnesium concentrations may be important for improving outcomes in patients with heart failure with reduced ejection fraction. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Magnesium Levels Impact Heart Failure Outcomes 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179 Summary: The TAILORED-CHIP trial randomized over two thousand high-risk patients undergoing complex percutaneous coronary intervention to either a tailored antiplatelet strategy involving early escalation and later de-escalation of platelet inhibition based on platelet function testing, or a standard antiplatelet regimen. The study found that the tailored approach did not significantly reduce the composite endpoint of death, myocardial infarction, stroke, or major bleeding at one year compared to the standard strategy. These results suggest that routine platelet function testing to guide antiplatelet therapy after complex percutaneous coronary intervention may not offer superior outcomes in high-risk patients. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial randomized over two thousand high-risk patients undergoing complex percutaneous coronary intervention to either a tailored antiplatelet strategy involving early escalation and later de-escalation of platelet inhibition based on platelet function testing, or a standard antiplatelet regimen. The study found that the tailored approach did not significantly reduce the composite endpoint of death, myocardial infarction, stroke, or major bleeding at one year compared to the standard strategy. These results suggest that routine platelet function testing to guide antiplatelet therapy after complex percutaneous coronary intervention may not offer superior outcomes in high-risk patients. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Tailored Antiplatelet Therapy Fails in CHIP PCI 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884771 Summary: This randomized controlled trial investigated ivabradine, a selective heart rate lowering agent, in patients undergoing noncardiac surgery to prevent myocardial injury after noncardiac surgery. The study found no significant reduction in myocardial injury after noncardiac surgery with ivabradine compared to placebo in patients aged 45 years or older with or at risk of atherosclerotic disease. These findings do not support routine use of ivabradine for prevention of myocardial injury after noncardiac surgery. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This randomized controlled trial investigated ivabradine, a selective heart rate lowering agent, in patients undergoing noncardiac surgery to prevent myocardial injury after noncardiac surgery. The study found no significant reduction in myocardial injury after noncardiac surgery with ivabradine compared to placebo in patients aged 45 years or older with or at risk of atherosclerotic disease. These findings do not support routine use of ivabradine for prevention of myocardial injury after noncardiac surgery. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Ivabradine Fails to Prevent Post-Surgery MINS 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124 Summary: This study investigated whether AI-ECG models serve as condition-specific classifiers or broader cardiovascular risk markers across four distinct populations. The findings reveal that AI-ECG models demonstrate phenotypic selectivity, exhibiting varying performance in detecting specific cardiac conditions versus predicting overall cardiovascular risk. This suggests the need for careful consideration of the intended clinical application when developing and deploying AI-ECG tools to avoid overgeneralization of results. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study investigated whether AI-ECG models serve as condition-specific classifiers or broader cardiovascular risk markers across four distinct populations. The findings reveal that AI-ECG models demonstrate phenotypic selectivity, exhibiting varying performance in detecting specific cardiac conditions versus predicting overall cardiovascular risk. This suggests the need for careful consideration of the intended clinical application when developing and deploying AI-ECG tools to avoid overgeneralization of results. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post AI-ECG Selectivity Impacts Diagnostic Accuracy 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884774 Summary: This multicenter trial investigates whether using a biomarker-based ABC-AF risk score to guide individualized treatment plans can improve outcomes in atrial fibrillation patients. The study aims to determine if this personalized approach reduces the risk of stroke or death compared to standard care. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. This multicenter trial investigates whether using a biomarker-based ABC-AF risk score to guide individualized treatment plans can improve outcomes in atrial fibrillation patients. The study aims to determine if this personalized approach reduces the risk of stroke or death compared to standard care. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post ABC-AF Score Guides AFib Therapy, Reduces Stroke 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884786 Summary: The PROTECT-TAVI trial found that cerebral embolic protection during TAVI did not significantly improve overall cognitive function at one year compared to TAVI alone. Although the study didn’t show a significant cognitive benefit, it underscores the ongoing need to refine embolic protection strategies for vulnerable TAVI patients. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. The PROTECT-TAVI trial found that cerebral embolic protection during TAVI did not significantly improve overall cognitive function at one year compared to TAVI alone. Although the study didn’t show a significant cognitive benefit, it underscores the ongoing need to refine embolic protection strategies for vulnerable TAVI patients. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post TAVI: No Cognitive Benefit From Embolic Protection 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886109 Summary: This international registry of mitral valve surgery patients provides real-world data on clinical presentation and outcomes. The MITRACURE registry aims to assess current practice, guideline adherence, and selection biases to improve the quality of mitral valve surgery. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. This international registry of mitral valve surgery patients provides real-world data on clinical presentation and outcomes. The MITRACURE registry aims to assess current practice, guideline adherence, and selection biases to improve the quality of mitral valve surgery. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Mitral Regurgitation Surgery Outcomes Registry Data 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421 Summary: This study found that in frail, older nursing home residents taking multiple antihypertensives with blood pressure under 130, a protocol-driven reduction in medication did not increase the risk of serious adverse events within six months. The findings suggest that de-escalation of antihypertensive therapy may be a safe approach in this vulnerable population, potentially reducing medication burden without compromising safety. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Reduction of Antihypertensive Treatment in Nursing Home Residents. This study found that in frail, older nursing home residents taking multiple antihypertensives with blood pressure under 130, a protocol-driven reduction in medication did not increase the risk of serious adverse events within six months. The findings suggest that de-escalation of antihypertensive therapy may be a safe approach in this vulnerable population, potentially reducing medication burden without compromising safety. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Antihypertensive Reduction Safe in Frail Elderly 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429 Summary: This randomized trial in Denmark investigated actively increasing potassium levels in high-risk ICD patients. The study will determine if maintaining high-normal potassium reduces ventricular arrhythmias in this vulnerable population. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This randomized trial in Denmark investigated actively increasing potassium levels in high-risk ICD patients. The study will determine if maintaining high-normal potassium reduces ventricular arrhythmias in this vulnerable population. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post High Potassium Reduces ICD Events? Trial Results 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431 Summary: This randomized trial in Italy showed that a multidomain intervention including cardiovascular risk factor control, dietary counseling, and exercise training improved physical performance and reduced major adverse cardiovascular events in older myocardial infarction patients with impaired physical performance, compared to usual care. This highlights the importance of comprehensive rehabilitation programs for improving outcomes in this vulnerable population. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This randomized trial in Italy showed that a multidomain intervention including cardiovascular risk factor control, dietary counseling, and exercise training improved physical performance and reduced major adverse cardiovascular events in older myocardial infarction patients with impaired physical performance, compared to usual care. This highlights the importance of comprehensive rehabilitation programs for improving outcomes in this vulnerable population. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Cardiac Rehab Boosts Function Post-MI in Elderly 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434 Summary: This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Digitoxin Fails to Improve Outcomes in HFrEF 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884219 Summary: This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. The gene therapy approach effectively targeted and corrected the genetic defect, offering a potential treatment strategy for this life-threatening condition. Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884211 Summary: This analysis of the REBOOT trial found no significant difference in the effect of beta-blockers post-MI with LVEF > 40 percent between men and women. These findings suggest that current guidelines for beta-blocker use after MI can be applied equally to both sexes, even with preserved ejection fraction. Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884202 Summary: This post hoc analysis of the LOOP study found an association between lower plasma potassium levels and increased daily atrial fibrillation (AF) burden in individuals at risk for stroke. Continuous ECG monitoring via implanted loop recorders allowed for the detection of these subtle, yet clinically relevant, potassium-AF associations. Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884168 Summary: This study demonstrated that circulating levels of imidazole propionate (ImP), a gut microbiota-derived metabolite, are associated with increased cardiometabolic risk in patients with coronary artery disease. ImP levels may serve as a prognostic biomarker for identifying high-risk CAD patients. Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884070 Summary: The EMPATICC trial investigated the safety and efficacy of heart failure therapies in patients with advanced cancer receiving specialized palliative care. The study aims to determine if these treatments can improve self-care ability in patients with cardiac wasting, dyspnea, and congestion. Article 6: Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884040 Summary: The POP-AF trial showed that a nurse-led, integrated lifestyle program improved outcomes after atrial fibrillation ablation. Patients receiving personalized lifestyle interventions experienced better ablation success compared to those receiving standard pre-ablation counseling. Article 7: Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884033 Summary: This large, retrospective study provides real-world incidence estimates for immune checkpoint inhibitor (ICI)-induced myocardial and muscle toxicities in cancer patients. The findings help to better define risk factors and prognostic indicators to improve management of these severe adverse drug reactions. Article 8: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884032 Summary: This detailed analysis of the VICTOR trial found that vericiguat did not significantly reduce cardiovascular mortality in patients with heart failure and reduced ejection fraction (HFrEF) without recent worsening. These findings suggest that vericiguat may not provide a mortality benefit in this specific patient population. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene thera

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886063 Summary: This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients. Article 2: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886061 Summary: The SEMA-VR CardioLink-15 trial demonstrates that semaglutide, a GLP-1RA, increases circulating vascular regenerative stem and progenitor cells. This suggests a potential mechanism by which semaglutide reduces cardiovascular events through promoting vessel repair and reducing atherothrombotic risk. Article 3: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886060 Summary: This study demonstrates the potential of CRISPR activation to upregulate FLNC gene expression in mice with truncating variants, leading to repair of ECG abnormalities. This offers a promising gene-specific therapeutic strategy for FLNCtv-induced cardiomyopathy, for which no current targeted therapies exist. Article 4: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884758 Summary: The DANCAVAS II trial evaluated population-based screening for cardiovascular disease in men aged 60-64. Results showed screening detected subclinical CVD but did not demonstrate significant all-cause mortality reduction within the trial’s timeframe. Article 5: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884757 Summary: The ANDAMAN trial investigated twice-daily aspirin dosing in ACS patients with diabetes or suspected aspirin resistance. The study found that twice-daily aspirin did not reduce major adverse cardiovascular events compared to standard dosing in this high-risk population. Article 6: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884558 Summary: The VICTORION-Difference trial demonstrates that inclisiran, a PCSK9 siRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia when used as part of a combination treatment strategy. These findings support the use of inclisiran to achieve LDL-C goals and reduce atherosclerotic cardiovascular disease risk. Article 7: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884439 Summary: This secondary analysis of the DAN-RSV trial examined the effectiveness of the RSVpreF vaccine in individuals with and without ASCVD. The study found no evidence that the vaccine reduces cardiovascular events in patients with pre-existing ASCVD, but did reduce respiratory illness. Article 8: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884413 Summary: standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. This analysis of the DANFLU-2 trial compared high-dose versus standard-dose influenza vaccines in adults with and without ASCVD. The study found no significant difference in cardiovascular or respiratory outcomes between the two vaccine types, regardless of ASCVD status. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Reticulated platelets in coronary artery disea

Welcome to Cardiology Today – Episode recorded on August 31, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884768 Summary: This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidence of bioprosthetic valve failure after TAVR, warranting longer-term follow-up. Article 2: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884047 Summary: The PRADA II trial demonstrated that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction in patients undergoing adjuvant breast cancer treatment with anthracyclines and/or trastuzumab. These findings do not support the routine use of sacubitril-valsartan for primary prevention of cardiotoxicity in this setting. Article 3: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879562 Summary: This study highlights the importance of intermediate-effect genetic variants (IEVs) in modulating the expression of hypertrophic cardiomyopathy (HCM). Understanding the clinical impact of these IEVs is crucial for unraveling the complex genetic architecture of HCM and improving risk stratification. Article 4: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878766 Summary: The DOUBLE-CHOICE trial showed that a minimalist anesthesia approach for transfemoral TAVI is non-inferior to standard of care regarding safety and efficacy. These results support the broader adoption of minimalist TAVI strategies to optimize resource utilization and patient outcomes. Article 5: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878676 Summary: This research identifies that in antiphospholipid syndrome (APS), the abnormal proliferation of microvascular endothelial cells leading to vasculopathy is driven by YAP1 and CCN2 signaling pathways. This discovery provides potential therapeutic targets for treating APS vasculopathy, where targeted treatment options are currently lacking. Article 6: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179 Summary: The TAILORED-CHIP trial found that a tailored antiplatelet strategy involving early escalation and subsequent de-escalation based on platelet function testing did not significantly reduce major adverse cardiovascular events compared to a standard antiplatelet strategy in high-risk patients undergoing complex PCI. This suggests that routine tailoring of antiplatelet therapy based on platelet function in this setting may not provide additional benefit. Article 7: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886161 Summary: This analysis of the GALACTIC-HF trial demonstrates that low serum magnesium concentrations are associated with increased risk of adverse cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The findings suggest that magnesium status may be an important prognostic marker in HFrEF. Article 8: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132 Summary: This study indicates that first-degree relatives of individuals with elevated lipoprotein(a) levels have an increased risk of cardiovascular events. Screening first-degree relatives for elevated Lp(a) may identify individuals at risk who could benefit from early intervention.

Welcome to Cardiology Today – your source for the latest cardiology research findings. Articles Featured in This Episode: Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434 Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431 Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429 Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421 Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109 Your browser does not support the audio element. Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.The post Cardiology Updates: Potassium, Rehab, and Novel Therapies 083125 first appeared on Cardiology Today.

Welcome to Cardiology Today – your source for the latest cardiology research findings. Articles Featured in This Episode: Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434 Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431 Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429 Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421 Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109 Your browser does not support the audio element. Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.The post Heart Failure, Potassium, and Mitral Valve Insights 083125 first appeared on Cardiology Today.